PitchBook clients can access this report’s Excel data pack via the Research Center on the PitchBook Platform.
How AI is reshaping biopharma
While AI is reshaping nearly every industry, its influence may prove most transformative in biopharma, where new technologies promise to address the high failure rate, lengthy development timelines, and escalating costs that characterize the industry. AI has already begun to provide tangible benefits: Early machine-learning-based computation tools have shifted wet-lab screening and validation processes in silico, while the debut of AlphaFold 2 in 2020 solved the protein-structure challenge, unlocking a significantly wider breadth of druggable targets and dramatically altering therapeutic design. The next frontier lies in multimodal systems capable of modeling cells to predict therapeutic response and toxicology and discover novel mechanisms—although data siloes remain a major barrier.
VC funding for AI drug development totaled $2.7 billion through the first three quarters of 2025. An emerging class of AI-native drug developers, using breakthrough models and computational tools to drive discovery and development, has attracted the majority of this capital and rapidly become some of the most well-funded startups in biopharma. Xaira Therapeutics, Isomorphic Labs, and Generate:Biomedicines all achieved unicorn status within their first two institutional rounds. Additionally, more asset-light AI tools and service providers are rapidly proliferating, with startups such as Lila Sciences, BenchSci, and Profluent pioneering AI-enabled discovery platforms.
Looking ahead, AI in biopharma is entering a crucial period of validation. With several AI-discovered drugs currently in clinical trials and leading startups such as Xaira Therapeutics and Isomorphic Labs likely to enter the clinic within the coming years, the clinical efficacy of AI-discovered assets will become clearer. While AI tools for experimental design and clinical-trial optimization will likely continue to be integrated into drug development, the success of AI-discovered assets will be the most significant benchmark for the technology and will have the greatest impact on the biopharma business model.
